Notably, there is an increasing trend in early-onset CRC (patients younger than 50 years), which currently accounts for approximately 10% of all new diagnoses ( 3 ).
← all excerpts
Methylation of NRIP3 Is a Synthetic Lethal Marker for Combined PI3K and ATR/ATM Inhibitors in Colorectal Cancer.
1
—
—